Cytokinetics
-
Cytokinetics begins patient enrollment in SEQUOIA-HCM phase 3 trial of aficamten to treat symptomatic obstructive hypertrophic cardiomyopathy
147 0Cytokinetics, Incorporated, a late-stage biopharmaceutical company, announced that SEQUOIA-HCM (Safety,…
Read more